This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harris, J. E. Articles by Hanna, M. G. Search for Related Content PubMed PubMed Citation Articles by Harris, J. E. Articles by Hanna, M. G., Jr Social Bookmarking                            What's this?

Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283

From the Rush-Presbyterian-St. Luke’s Medical Center; Northwestern University School of Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Lehigh Valley Hospital, Allentown, PA; Medical University of South Carolina, Charleston, SC; University of Minnesota, Minneapolis, MN; Case Western Reserve University MetroHealth Medical Center, Cleveland, OH; University of Pennsylvania, Philadelphia, PA; and Intracel Corporation, Rockville, MD.

Address reprint requests to Jules E. Harris, MD, Section of Medical Oncology, Rush-Presbyterian-St. Luke’s Medical Center, 1725 W Harrison St, Chicago, IL 60612; email jharris{at}rush.edu

PURPOSE: A randomized phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor cell–bacillus Calmette-Guérin (BCG) vaccine was conducted to determine whether surgical resection plus ASI was more beneficial than resection alone in stage II and III colon cancer patients.

PATIENTS AND METHODS: Patients (n = 412) with colon cancer (297 with stage II disease, 115 with stage III disease) were randomly allocated to an observation arm or to a treatment arm in which they received three weekly intradermal vaccine injections of 10⁷ irradiated autologous tumor cells beginning approximately 4 weeks after surgery. The first two weekly injections also contained 10⁷ BCG organisms. Patients were observed for determination of time to recurrence and disease-free and overall survival.

RESULTS: This was a negative study in that after a 7.6-year median follow-up period, there were no statistically significant differences in clinical outcomes between the treatment arms. However, there were disease-free survival (P = .078) and overall survival (P = .12) trends in favor of ASI when treatment compliance was evaluated, ie, patients who received the intended treatment had a delayed cutaneous hypersensitivity (DCH) response to the third vaccination (induration 5 mm). Also, the magnitude of the DCH response correlated with improved prognosis. The 5-year survival proportion was 84.6% for those with indurations greater than 10 mm, compared with 45.0% for those with indurations less than 5 mm.

CONCLUSIONS: When all randomized patients were evaluated, no significant clinical benefit was seen with ASI in surgically resected colon cancer patients with stage II or III colon cancer. However, there was an indication that treatment compliance with effective immunization results in disease-free and overall survival benefits.

The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Itoh, A. Yamada, T. Mine, and M. Noguchi Recent Advances in Cancer Vaccines: An Overview Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 73 - 80. [Abstract] [Full Text] [PDF]

				M. C. Posner, D. Niedzwiecki, A. P. Venook, D. R. Hollis, H. L. Kindler, E. W. Martin, R. L. Schilsky, R. M. Goldberg, and for the Cancer and Leukemia Group B A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903 Ann. Surg. Oncol., January 1, 2008; 15(1): 158 - 164. [Abstract] [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, and J.-Y. Douillard Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials J Natl Cancer Inst, July 4, 2007; 99(13): 998 - 1003. [Abstract] [Full Text] [PDF]

				D. Nagorsen and E. Thiel Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., May 15, 2006; 12(10): 3064 - 3069. [Abstract] [Full Text] [PDF]

				D. P. Carbone, I. F. Ciernik, M. J. Kelley, M. C. Smith, S. Nadaf, D. Kavanaugh, V. E. Maher, M. Stipanov, D. Contois, B. E. Johnson, et al. Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome J. Clin. Oncol., August 1, 2005; 23(22): 5099 - 5107. [Abstract] [Full Text] [PDF]

				K. A. Skinner Antitumor Vaccines: Of Mice and Men? Ann. Surg. Oncol., July 1, 2005; 12(7): 511 - 512. [Full Text] [PDF]

				S. Mosolits, G. Ullenhag, and H. Mellstedt Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results Ann. Onc., June 1, 2005; 16(6): 847 - 862. [Abstract] [Full Text] [PDF]

				A. Zaniboni and R. Labianca Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Onc., September 1, 2004; 15(9): 1310 - 1318. [Abstract] [Full Text] [PDF]

				A. Figueredo, M. L. Charette, J. Maroun, M. C. Brouwers, and L. Zuraw Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group J. Clin. Oncol., August 15, 2004; 22(16): 3395 - 3407. [Abstract] [Full Text] [PDF]

				M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF]

				V. Mazzaferro, J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, et al. Vaccination with Autologous Tumor-derived Heat-Shock Protein Gp96 after Liver Resection for Metastatic Colorectal Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3235 - 3245. [Abstract] [Full Text] [PDF]

				G. Pentheroudakis and N. Pavlidis Immunomodulation in colorectal cancer: disappointment or promise? Ann. Onc., March 1, 2003; 14(3): 349 - 351. [Full Text] [PDF]

				C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]

				E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al. Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion Cancer Res., October 1, 2002; 62(19): 5495 - 5504. [Abstract] [Full Text] [PDF]

				I. Espinoza-Delgado Cancer Vaccines Oncologist, August 1, 2002; 7(90003): 20 - 33. [Abstract] [Full Text] [PDF]

				S. Dermime, A. Armstrong, R. E Hawkins, and P. L Stern Cancer vaccines and immunotherapy Br. Med. Bull., July 1, 2002; 62(1): 149 - 162. [Abstract] [Full Text] [PDF]

				A C Armstrong and R E Hawkins Vaccines in oncology: background and clinical potential Br. J. Radiol., November 1, 2001; 74(887): 991 - 1002. [Abstract] [Full Text] [PDF]

				V. K. Sondak and A. E. Chang Treating Colon Cancer With a Melanoma Vaccine? Preposterous? Ann. Surg. Oncol., June 1, 2001; 8(5): 386 - 388. [Full Text] [PDF]

				N. Habal, R. K. Gupta, A. J. Bilchik, R. Yee, Z. Leopoldo, W. Ye, R. M. Elashoff, and D. L. Morton CancerVax, An Allogeneic Tumor Cell Vaccine, Induces Specific Humoral and Cellular Immune Responses in Advanced Colon Cancer Ann. Surg. Oncol., June 1, 2001; 8(5): 389 - 401. [Abstract] [Full Text] [PDF]